Orphan Therapeutics Market: Key Players, Growth, Analysis by 2019 – 2027

 Orphan Therapeutics Market information, by Type of Diseases (autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and Others), by Type of Treatment (gene therapy, cell therapy, drug therapy and others), by End user (hospital and clinics, research laboratory and others) - Forecast to 2022

Orphan Therapeutics Market are also referred to as rare diseases. Despite the low market interest, treatment demand continues to grow for orphan diseases. Orphan diseases represent a very small percentage of the global population. However, prevalence rate has increased considerably in recent years. Most orphan diseases are genetic and may remain in patient throughout their life. While many orphan diseases are low-risk and do not threaten life, some may have severe impact on the health. Approximately 7000 different rare diseases are listed, however, no exact figure is available.

The market for orphan diseases is growing swiftly. Rising level of awareness and increased funding is reflecting favourably on the market. According to a study conducted by market research future, the global Orphan Therapeutics Market is projected to demonstrate a compound annual growth rate (CAGR) of 24.9% during the forecast period (2015-2022). The market size is expected to surpass USD 500 Bn by the year 2022 up from USD 121.6 Bn.

Demand for orphan drugs has grown substantially in recent years. Many governments all around the world are financially incentivising drugs through regulations. A data released by National Organization for Rare Disorders (NORD), reveals that in 2018, nearly 30 Mn Americans suffer from 7,000 rare diseases. More and more initiatives are taken towards improving orphan disease care. This is notable for advanced countries such as the U.S., Japan and EU countries. Over the past couple years, orphan drug sales have doubled.

Factors such as increased prevalence and rising healthcare expenditure are making the market more attractive. Commercial interest in orphan diseases drugs have improved in recent years. Advanced are likely to display a higher enthusiasm. When it comes of research and development smaller firms and start-ups are more active, however some of the bigger players are also positioning themselves to enter the segment. In the comings, collaborations, partnerships and M&A activities are expected to increase in the global Orphan Therapeutics Market. Big pharmaceutical companies are expected to focus on improving their market position during the forecast period.

Global Orphan Therapeutics Market: Segmental Overview

MRFR’s report includes a detailed segmental analysis of the market based on disease, treatment and end user.

On the basis of disease, the market has been segmented into genetic disorders, cancer, cardiovascular diseases, respiratory disorders, autoimmune disorders, neurological disorders, blood disorders, eye disorders, digestive disorders, growth disorder and others. On the basis of treatment, the market has been segmented into drug therapy, cell therapy, gene therapy and others. Based on end user, the market has been segmented into research laboratory, hospital and clinics and others.

Browse Complete Report :https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547

Global Orphan Therapeutics Market: Regional Segmentation

The regions covered in the market include Asia Pacific (APAC), North America, Europe, Latin America, and the Middle East & Africa (MEA). Globally, North America represents the largest market for orphan diseases. Widespread awareness, strong government support and presence of robust healthcare system supports the market growth in the region. North America Orphan Therapeutics Market is expected to post a sound growth during the forecast period. Europe also holds significant market potentials and second largest contributor to the global market for orphan diseases in terms of revenue. North America and Europe are followed by Asia Pacific (APAC). In fact, the APAC Orphan Therapeutics Market is likely to witness an impressive growth over the next couple of years.

Competitive Landscape

Some of the top-notch companies operating in the global Orphan Therapeutics Market include F. Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), CELGENE CORPORATION (US), Merck & Co., Inc (US), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), AbbVie Inc. (US), Sanofi (French), Alexion (US), GlaxoSmithKline plc. (UK) and Pfizer Inc. (US).

 

life science and analytical instruments market Overview: Type and Applications, Trends, Industry Analysis & Forecast, 2018-2027

 The global life science and analytical instruments market was valued at USD 36.5 billion in 2016, according to the latest research report from Market Research Future (MRFR). Growing at a robust 6.5% CAGR over the forecast period from 2017 to 2023, the market is expected to rise to a valuation of USD 56.7 billion, according to the MRFR study. The report presents a clear profile of the market, including competitive dynamics, major drivers, restraints, and other economic factors having a key impact on the market, and the leading players operating in the market. Key events in the market’s history over the review period are also analyzed in the report to provide readers with some background. A detailed projection for the market’s growth trajectory over the forecast period from 2017 to 2023 is presented in the report.

The life science and analytical instruments market is mainly driven by the growth of the life sciences sector in recent years. Growth of the healthcare sector and the increasing government investment in drug development and research have been the major drivers for the life sciences sector in recent years. With the growing scope of the life sciences sector, the demand for life science instrumentation has grown rapidly over the last few years. Increasing prevalence of cancer, infectious diseases, and lifestyle diseases such as diabetes and hypertension has led to a growing demand from the life sciences sector, as the need for effective medication against these and other diseases has grown.

Increasing demand for life science and analytical instruments in genetic studies and research in biotechnology processes is likely to be a major driver for the global life science and analytical instruments market over the forecast period. The biotechnology sector is likely to be a major part of the life sciences sector in the coming years due to the growing demand for recombinant DNA technology, among others, in drug development and research. This is likely to be a key driver for the global life science and analytical instruments market over the forecast period.

Request Free Sample: https://www.marketresearchfuture.com/sample_request/825 

Competitive Analysis:

Leading players in the global life science and analytical instruments market include Merck KGaA, Dynalabs, Avista Pharma Solutions, Paragon Bioservices Inc., Avance Biosciences, Charles River Laboratories International Inc., Waters Corporation, Shimadzu Corporation, PerkinElmer Inc., Danaher Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., F. Hoffman-La Roche Ltd., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Becton Dickinson and Company.

In October 2019, Bruker Corporation announced the acquisition of Magnettech’s EPR business.

Segmentation:

The global life science and analytical instruments market is segmented on the basis of instrument type, end use, application, and region.

By instrument type, the global life science and analytical instruments market is segmented into centrifuges, chromatography, electrophoresis, flow cytometry, microscopy, cell counting instruments, PCR, spectroscopy, Western blotting, and others. The centrifuges segment is further subdivided into laboratory centrifuges, analytical ultracentrifuges, gas centrifuges, and others. The chromatography segment is further sub-segmented into thin-layer chromatography, liquid chromatography, gas chromatography, HPTLC, and others. The electrophoresis segment is further subdivided into conventional and capillary electrophoresis. Microscopy is further sub-segmented into scanning electron microscopes, transmission electron microscopes, and others. The spectroscopy segment is further sub-segmented into mass spectroscopy, UV spectroscopy, atomic spectroscopy, and others.

By end use, the global life science and analytical instruments market is segmented into agriculture and food industry, pharmaceutical and biotechnology companies, research and clinical testing laboratories, and others.

By application, the global life science and analytical instruments market is segmented into research, diagnostic, and others.

Browse Complete Report:https://www.marketresearchfuture.com/reports/life-science-analytical-instruments-market-825 

Regional Analysis:

North America is the leading regional life science and analytical instruments market, followed by Europe. The growing presence of drug discovery operations in North America has driven the demand for life science and analytical instruments in recent years. The increasing number of research studies in the healthcare sector is also likely to be a major driver for the life science and analytical instruments market in North America over the forecast period.

Bronchodilators Market : Latest Innovations, Drivers and Industry Key Events 2018 – 2027

 According to MRFR analysis, Bronchodilators Market is expected to register a CAGR of 5.30% during the forecast period of 2019 to 2025 and is expected to reach USD 2,484 Million by 2025.

Market Highlights

Bronchodilators are medications that make breathing easier by opening the airways of the lung by relaxing bronchial muscles. They are used to treat various respiratory problems such as asthma, COPD, and other allergic reactions that cause breathing problems.

The growth of the global bronchodilators market is driven by various factors such as increase in prevalence of pulmonary disorders, increasing geriatric population and increasing mergers and acquisitions by prominent players in the market. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of the bronchodilators are projected to hamper the growth of the global bronchodilators market.

The global bronchodilators market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in April 2019, Cipla Technologies entered into agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Segmentation

The global bronchodilators market has been segmented based on drug type, disease, mode of action, and route of administration.

The market, based on drug type, has been divided into adrenergic drugs, anticholinergics, a phosphodiesterase inhibitor, and combination drugs.

The adrenergic segment is likely to be the largest during the review period as they are the most potent bronchodilators approved for clinical use in asthma and obstructive lung disease. The combination drugs segment is predicted to be the fastest-growing segment. These combination drugs are used if COPD and asthma are not controlled with monotherapy. These combinations involving two long-acting bronchodilators with differing modes of action.

The global bronchodilators market has been segmented, on the basis of disease, into asthma, COPD, and others. The asthma segment is expected to hold the majority share of the market, owing to the rise in patients affected with asthma. The COPD segment is expected to be the fastest-growing as bronchodilators are primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation.

In terms of mode of action, the global bronchodilators market has been segmented into short-acting bronchodilators and long-acting bronchodilators. Short-acting bronchodilators are expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness.

The route of administration of the market is oral and parenteral. The oral route of administration segment is expected to hold the largest share of the market due to the advantages such as ease and simplicity of administration along with control of delivered dose.

Key Players

Some of the key players in the Global Bronchodilators Market are GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), F. Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel) and Pfizer Inc. (US) among others.

Access Report Details @ https://www.marketresearchfuture.com/reports/bronchodilators-market-8453

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are expected to be the largest market owing to the rising per capita healthcare expenditure. The bronchodilators market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European bronchodilators market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The bronchodilators market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of respiratory disorders and the increasing pool of patient population, the market in Asia-Pacific is expected to be the fastest-growing. The bronchodilators market in the Middle East & Africa has been divided into the Middle East and Africa.

Anxiety Disorder Treatment Market Share : Recent Industry Trends, Analysis and Forecast 2027

 Market Forecast

Registering a CAGR of 5.4%, Anxiety Disorder Treatment Market Share is expected to reach USD 16.96 Million by 2025.

People with anxiety disorders may feel anxious most of the time or for the brief, intense episodes, which may occur for no apparent reason. The main categories of anxiety disorders include phobia, panic disorder, generalized anxiety disorder, social anxiety disorder, selective mutism, and separation anxiety disorder.  

Numerous established players dominate the market. The key players are involved in strategic initiatives to strengthen their market positions and expand their geographic presence in developing regions. Many players are investing in research activities to develop effective therapies to sustain in the market. For instance, Eli Lilly and Company launched Duloxetine and Forest Laboratories, Inc. launched Vilazodone, used for the treatment of generalized anxiety disorder.  

Market Influencers

Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major key players are positively influencing the market.  

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global Anxiety Disorder Treatment Market Share owing to the rising incidence of anxiety disorders in the region. For instance, generalized anxiety disorder affects 6.8 million adults, or 3.1% of the US population every year. Moreover, rising awareness campaigns regarding the anxiety disorders by the government and public organizations is driving the growth of the market in this region. For instance, the Anxiety and Depression Association of America (ADAA) started an initiative named BreaktheStigma. This campaign raises awareness regarding mental illness and end stigma and creates hope for those affected by mental illness.

Europe is expected to hold the second-largest position in the global Anxiety Disorder Treatment Market Share owing to supportive government policies and raising public awareness about anxiety disorder treatments.

Asia-Pacific is anticipated to be the fastest-growing region is due to the growing prevalence of psychological conditions such as anxiety disorders, rising interest of major key players in emerging markets, good quality healthcare infrastructure in this region. The Middle East & Africa has the least share of the global Anxiety Disorder Treatment Market Share. This is attributable to limited healthcare infrastructure and a lack of awareness about anxiety disorder treatments in this region.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/anxiety-disorder-treatment-market-8455

Segmentation

The Global Anxiety Disorder Treatment Market Share has been segmented into drug class and end-user.

By drug class, the market has been segmented into SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants),      pregabalin, buspirone, benzodiazepines, and others.

The global Anxiety Disorder Treatment Market Share, by end-user, has been segmented into hospitals, mental healthcare centers, asylums, and others.

Key Players

• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Johnson & Johnson (US)
• AstraZeneca PLC (UK)
• Sanofi-Aventis (France)
• Forest Laboratories, Inc. (US)
• Pfizer, Inc. (US)
• GlaxoSmithKline PLC (UK)
• Lundbeck A/S (Denmark)
• Merck & Co., Inc. (US)

 

Pharmacovigilance Market 2018-2027: Overview by Types, Application, Key Players, Regional Outlook, Market Drivers & Restraints

 Market Highlights

According to MRFR analysis, Pharmacovigilance Market is expected to register a CAGR of 14.1% during the forecast period of 2019 to 2025 and accounts for USD 4321.86 Million 2018.

Pharmacovigilance supports safe and appropriate use of drugs by identifying risk factors for the development of adverse drug reactions (ADR), promoting the detection of previously unknown ADR and their interactions with known ADR.

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, on May 16, 2019, Accenture launched INTENT to improve the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.

Segmentation

The Global Pharmacovigilance Market has been segmented based on the clinical trial phase, service provider, type, and end-user.

The market, based on the clinical trial phase, has been divided into phase IV, phase III, phase II, phase I, and pre-clinical. Phase IV segment dominated the pharmacovigilance market as adverse drug reactions are majorly detected in this phase. Whereas, phase III is expected to witness the fastest growth.

The global pharmacovigilance market has been segmented, on the basis of service provider, into in-house and contract outsourcing. Contract outsourcing dominated the global pharmacovigilance market and expected to witness the fastest growth. Contract manufacturing serves multiple customers and thus can acquire raw materials at a reduced cost, benefiting from the economies of scale.  

The market, based on type, has been divided into spontaneous reporting, cohort event monitoring, intensified ADR reporting, targeted spontaneous reporting, and EHR mining. The spontaneous reporting held largest market share in 2018. Spontaneous reporting is a passive approach to pharmacovigilance as it entirely relies on the motivation of individuals to report suspected ADRs to a local or national pharmacovigilance center.

In terms of end-user, the global pharmacovigilance market has been segmented into hospitals, research organizations, pharmaceutical companies, and others. Hospitals take up the largest share due to an increase in the number of hospital admissions due to ADRs.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/pharmacovigilance-market-8451

Key Players

Some of the key players in the Global Pharmacovigilance Market are Accenture (Ireland), ArisGlobal (US), BioClinica (US), Capgemini (France), Conquest Group BV (Netherlands), Cognizant (US), IBM Corporation (US), ICON PLC (Ireland), IMEDGlobal (US), ITClinical (Portugal), Laboratory Corporation of America Holdings (US), PAREXEL International Corporation (US), TAKE Solutions Ltd (India), United BioSource Corporation (US), and Wipro Ltd (India).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the high spending by the pharmaceutical industry. The pharmacovigilance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European Pharmacovigilance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pharmacovigilance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of chronic conditions and rising cases of ADRs and medication errors, the market in Asia-Pacific is expected to be the fastest-growing. The pharmacovigilance market in the Middle East & Africa has been divided into the Middle East and Africa.

 

 

Gene Therapy Market Segmentation, Dynamics, Market Size, Supply & Demand, Competition & Companies, Drivers, Restraints and Technology

 Market Insights

According to Market Research Future, the global Gene Therapy Market is estimated to reach the highest market share with a growth rate of 40.7% during the forecast period, at a market size of USD 524 million.

 

Gene therapy is a method in which a slice of DNA is introduced into the cell through a vector. The most important players invest in the production of cell and gene therapy treatments due to their specific target. Gene therapy consists mainly of two types, somatic gene therapy, and germline gene therapy, depending on the target cell type. The progress of the global gene therapy market is ascribed to several factors, such as the robustness of the product portfolio, the growing investments of the main players, the high prevalence of target diseases, and the demand for innovative medicines. However, the high costs of product development and stringent regulatory policies should slow the development of the global gene therapy market. The global gene therapy market is currently influenced by several market participants. Key players are engaged in strategic partnerships and product launches to strengthen their market positions.

 

Market Segmentation

The global gene therapy market is classified by product, indication, and end-user.

 The product-based market is divided into kymriah, yescarta, luxturna, zynteglo, zolgensma, strimvelis, imlygic, and others.  The kymriah subsegment leads the product segment as it was the first gene therapy approved in the US

The global indication-based gene therapy market is segmented into oncology, genetic diseases / disorders, and so on. The oncology segment is expected to have the largest market share and the fastest-growing segment due to the high prevalence of cancer and the robustness of cancer gene therapy.

The end-user segments of the market are hospitals and clinics, specialized treatment centers, and others. The clinic and hospital segment are expected to have the largest market share due to the growing number of hospitals. In addition, hospitals are usually the first choice for treating illnesses.

 

Regional Insights

Region-wise the global market is split into various regional markets such as the Americas, Asia Pacific, Europe, and the Middle East & Africa.

North America leads regionwise in the global market in terms of share owing to high number of approved molecules for clinical usage and increased research and development for gene studies.

Following the US, Europe's high molecule approval stands at the second position and is anticipated to sustain its position during the forecast period.

A developing region such as India and China in Asia Pacific region is predicted to offer lucrative growth prospects owing to progressive growth in the field genes and molecular biology.

 

Browse Complete Report: https://www.marketresearchfuture.com/reports/gene-therapy-market-8399

 

Market Players

The leading names involved in the growth of the global gene therapy market include Amgen, Inc., Novartis AG, Spark Therapeutics, Inc., Gilead Sciences, Inc., uniQure N.V., Orchard Therapeutics plc, Celgene Corporation, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., CEVEC, and Lonza. Manufacturers emphasizing the investment for advanced microbiology research and efforts to stay competitive in the global market is one of the driving factors responsible for the growth of the global market.

 

Industry Updates

• Pfizer and Novartis lead a wave of pharmaceutical spending on gene therapy. According to a Reuters analysis, eleven pharmaceutical companies led by Pfizer and Novartis have allocated $ 2 billion jointly since 2018 to invest in the gene therapy industry to better control the production of the world's most expensive drugs.

 

osseointegration implants market Playing for Significant Growth During 2017 – 2027

 

Osseointegration Implants Market Synopsis:

The report published by Market Research Future (MRFR) asserts that the global osseointegration implants market is marked to expand at a notable CAGR of 6.4% during the forecast period of 2017-2023 and reach the valuation of USD 6.8 Bn by the end of the forecast period from USD 4.7 Bn in 2017. Rapid advancement in technology is contributing significantly in improving the treatment procedures to provide quick relief and effective remedy for various health conditions. Recent developments of osseointegration technique that has improved the bone and joint replacement procedures and increasing demand for cosmetic dentistry are majorly propelling the growth of the global osseointegration implants market. Innovation in the materials utilized for osseointegration implants and the ability of osseointegration implants to provide stability the prostheses and implants are inducing high demand for these implants, leading to the expansion of the global osseointegration implants market. However, complexities during the procedure and risk of bone damage associated with the implants are acting as the restraining factors for the expansion of the global osseointegration implants market during the assessment period.

Market Segmentation:

The Global Osseointegration Implants Market has been segmented on the basis of product, material type and end-users. Based on product, the osseointegration market has been segmented into bone-anchored prostheses, dental implants and others. The bone-anchored prostheses segment command the major share in the global osseointegration implants market. Whereas, the dental implants segment projects the fastest growth in the global osseointegration implants market. Based on material type, the global osseointegration implants market has been segmented into metallic, ceramic, polymeric and others. The metallic segment commands the largest share in the global osseointegration implants market. The ceramic segment is forecasted to project the fastest growth in the global osseointegration implants market during the assessment period. Based on end-users, the global osseointegration implants market has been segmented into hospitals, ambulatory surgical clinics and others. The hospitals segment command the dominant share in the global osseointegration market. Whereas, the ambulatory surgical clinics segment is marked to project the fastest growth in the global osseointegration implants market during the forecast period.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/osseointegration-implants-market-6740

Key Players:

The key players operating in the global osseointegration implants market are Zimmer Biomet Holdings Inc., Dentsply Sirona Inc., Danaher Corporation, The Straumann Group, Henry Schein Inc., Stryker Corporation, NuVasive, Inc., William Demant Holding A/S, Cochlear Ltd., and Medtronic plc. The players in the global osseointegration implants market are aiming towards business expansion by increasing investments in research and development of innovative products in the global market along with strategizing mergers and acquisitions in the global osseointegration implants market during the forecast period.

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6740

Regional Analysis:

The global osseointegration implants market has been geographically segmented into four major regions such as the Americas, Europe, Asia Pacific, and the Middle East and Africa. The osteointegration implants market in the Americas is expanding at a noteworthy growth rate owing to the easy adoption of technologically advanced treatment solutions in the well-developed healthcare sector, increasing popularity of cosmetic dentistry and high healthcare expenditure by the population of this region. The Europe region is anticipated to expand notably in the global osseointegration implants market owing to the rise in research and development expenditure for the launch of innovative products and materials to be utilized for carrying out osseointegration implant procedures and rapid development of osseointegration techniques in the healthcare sector of this region. The osseointegration implants market in the Asia Pacific region is marked to expand significantly in the global market owing to the high demand for these implants in the emerging economies of this region as a result of rapid rise in geriatric population and increased number of individuals undergoing dental implants in this region. Lack of awareness and absence of primary healthcare facilities in the underdeveloped areas are impacting negatively on the expansion of the osseointegration implants market in the Middle East and Africa region.